#ASCO22: Gilead’s Trodelvy shows slim benefit in common form of breast cancer

In March, Gilead drew ire from analysts for releasing an upbeat Q&A without any hard data for its latest Trodelvy trial, which put into question whether the big biotech’s drug would be effective in one of the most common forms of breast cancer. Now, the data are finally here, showing…

...

Click to view original post